Piramal Pharma Limited (PPLPHARMA.NS)
INR 220.41
(-0.64%)
INR 220.41
(-0.64%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 24.47 Billion INR | -44.11% |
| 2022 | 43.78 Billion INR | 183.16% |
| 2021 | 15.46 Billion INR | -6.88% |
| 2020 | 16.6 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 14.45 Billion INR | 35.32% |
| 2024 Q1 | 5.12 Billion INR | -39.54% |
| 2023 Q1 | 11.22 Billion INR | -15.24% |
| 2023 FY | 24.47 Billion INR | -44.11% |
| 2023 Q4 | 8.47 Billion INR | -33.95% |
| 2023 Q3 | 12.83 Billion INR | 0.77% |
| 2023 Q2 | 12.73 Billion INR | 13.5% |
| 2022 Q1 | 9.07 Billion INR | 171.45% |
| 2022 FY | 43.78 Billion INR | 183.16% |
| 2022 Q4 | 13.23 Billion INR | 21.38% |
| 2022 Q3 | 10.9 Billion INR | 3.28% |
| 2022 Q2 | 10.56 Billion INR | 16.35% |
| 2021 Q1 | 9.3 Billion INR | 0.0% |
| 2021 FY | 15.46 Billion INR | -6.88% |
| 2021 Q4 | -12.7 Billion INR | -228.09% |
| 2021 Q3 | 9.91 Billion INR | 2.08% |
| 2021 Q2 | 9.71 Billion INR | 4.36% |
| 2020 FY | 16.6 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Biocon Limited | 91.73 Billion INR | 73.324% |
| Blue Jet Healthcare Limited | 3.15 Billion INR | -674.589% |
| Concord Biotech Limited | 7.56 Billion INR | -223.498% |
| Dishman Carbogen Amcis Limited | 4.9 Billion INR | -399.019% |
| Jubilant Ingrevia Limited | 9.16 Billion INR | -166.976% |
| Lyka Labs Limited | 145.95 Million INR | -16666.403% |
| Panacea Biotec Limited | 1.42 Billion INR | -1614.009% |
| SMS Lifesciences India Limited | 329.57 Million INR | -7324.964% |
| Supriya Lifescience Limited | 2.65 Billion INR | -822.803% |
| Syngene International Limited | 12.43 Billion INR | -96.743% |
| TAKE Solutions Limited | 183.42 Million INR | -13241.457% |
| Zota Health Care Limited | 332.52 Million INR | -7259.072% |